XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EQUITY (Tables)
6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK

 

   Number of
underlying
Common stock
   Exercise price   Expiration date  
Series E Warrants   198,159   $27.000  September 24, 2024  
Series F Warrants   433,878   $7.4250  June 5, 2025-October 16, 2025  
Series G Warrants   1,092,344   $10.230  February 8, 2026  
Series I Warrants   12,914,078   $1.3827 

-*

 
Series J Warrants   12,914,086   $1.3827 

-*

 
Series K Warrants   12,914,078   $1.3827 

-*

 
Underwriter Warrants   12,965   $7.4250 

September 24, 2024

 
Total Warrants   40,479,588         

 

The Warrants have a term of the earlier of (i) May 15, 2025 and (ii) (A) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (B) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (C) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.